Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression

Clinical Breast Cancer

Volumn 14, Issue 4, 2014, Pages 258-264

  Balduzzi, Alessandra ^a   Bagnardi, Vincenzo ^a,b   Rotmensz, Nicole ^a   Dellapasqua, Silvia ^a   Montagna, Emilia ^a   Cardillo, Anna ^a   Viale, Giuseppe ^a,c   Veronesi, Paolo ^a,c   Intra, Mattia ^a   Luini, Alberto ^a   Pruneri, Giancarlo ^a,c   Mastropasqua, Giuseppe ^a   Goldhirsch, Aron ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Adjuvant treatment; Estrogen receptor; Histologic subtypes; Low endocrine responsiveness; Overall survival

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PATIENT CODING; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR INVASION; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84904617944     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.10.019     Document Type: Article

References (28)

1. G.M. Clark, C.K. Osborne, and W.L. McGuire Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer J Clin Oncol 2 1984 1102 1109 (Pubitemid 14022697)
2. V.J. Bardou, G. Arpino, and R.M. Elledge et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases J Clin Oncol 21 2003 1973 1979 (Pubitemid 46606386)
3. M.E. Lippman, J.C. Allegra, and E.B. Thompson et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer N Engl J Med 298 1978 1223 1228 (Pubitemid 8357640)
4. D.A. Berry, C. Cirrincione, and I.C. Henderson et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 2006 1658 1667
5. A. Goldhirsch, J.H. Glick, and R.D. Gelber et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 2005 1569 1583 (Pubitemid 41511089)
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
7. C.M. Perou, T. Sorlie, and M.B. Eisen et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
8. T. Sorlie, C.M. Perou, and R. Tibshirani et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874 (Pubitemid 32878711)
9. M.M. Regan, G. Viale, and M.G. Mastropasqua et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays J Natl Cancer Inst 98 2006 1571 1581 (Pubitemid 44680908)
10. T. Phillips, G. Murray, and K. Wakamiya et al. Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy Appl Immunohistochem Mol Morphol 15 2007 325 331 (Pubitemid 47329926)
11. G. Viale, M.M. Regan, and E. Maiorano et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 J Clin Oncol 25 2007 3846 3852 (Pubitemid 47477259)
12. M. Dowsett, C. Allred, and J. Knox et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal grown factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial J Clin Oncol 26 2008 1059 1065
13. G. Viale, M.M. Regan, and E. Maiorano et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group J Clin Oncol 26 2008 1404 1410
14. A. Giobbie-Hurder, K.N. Price, R.D. Gelber International Breast Cancer Study Group BIG 1-98 Collaborative Group Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer Clin Trials 6 2009 272 287
15. M.E. Hammond, D.F. Hayes, and M. Dowsett et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2010 2784 2795
16. A. Goldhirsch, J.N. Ingle, and R.D. Gelber et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 Ann Oncol 20 2009 1319 1329
17. A. Goldhirsch, J.H. Glick, and R.D. Gelber et al. Meeting highlights: International Consensus Panel On the Treatment Of Primary Breast Cancer J Natl Cancer Inst 90 1998 1601 1608 (Pubitemid 28523434)
18. A. Goldhirsch, J.H. Glick, and R.D. Gelber et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer J Clin Oncol 19 2001 3817 3827 (Pubitemid 32880060)
19. C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 1991 403 410
20. M. Colleoni, E. Orvieto, and F. Nolè et al. Prediction of response to primary chemotherapy for operable breast cancer Eur J Cancer 35 1999 574 579 (Pubitemid 29192965)
21. M.C. Cheang, S.K. Chia, and D. Voduc et al. Ki67 Index, HER2 status, and prognosis of patients with Luminal B breast cancer J Natl Cancer Inst 101 2009 736 750
22. N. Honma, G. Sakamoto, and F. Akiyama et al. Breast carcinoma in women over the age of 85: distinct histological pattern an androgen, oestrogen, and progesterone receptor status Histopathology 42 2003 120 127 (Pubitemid 36237843)
23. D.C. Allred, R.W. Carlson, and D.A. Berry et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry J Natl Compr Canc Netw 7 suppl 6 2009 S1 21
24. C.S. Thompson, C.J. Twelves, and E.A. Mallon et al. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status Breast 11 2002 419 429 (Pubitemid 35469501)
25. L.C. Collins, M.L. Botero, and S.J. Schnitt Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases Am J Clin Pathol 123 2005 16 20 (Pubitemid 40066167)
26. J.M. Harvey, G.M. Clark, and C.K. Osborne et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1999 1474 1481 (Pubitemid 29220854)
27. K.P. Raghav, L.F. Hernandez-Aya, and X. Lei et al. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancer previously classified as triple negative breast cancers Cancer 118 2012 1498 1506
28. T. Iwamoto, D. Booser, and V. Valero et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancer that are 1% to 10% ER-positive by immunohistochemistry J Clin Oncol 30 2012 729 734